التفاصيل البيبلوغرافية
| العنوان: |
Characteristics of patients with late recurrence endometrial cancer. |
| المؤلفون: |
Çakır, İlker, Gülseren, Varol, Özdemir, İsa Aykut, Abacı, Hüseyin, Talu, Esra Canan Kelten, Çakır, Zübeyde Emiralioğlu, Ata, Can, Kuru, Oğuzhan, Gökçü, Mehmet, Sancı, Muzaffer, Güngördük, Kemal |
| المصدر: |
Journal of Cancer Research & Therapeutics; Jan-Mar2024, Vol. 20, p232-237, 6p |
| مصطلحات موضوعية: |
CANCER relapse, ENDOMETRIAL cancer, DISEASE relapse, PROGRESSION-free survival, OVERALL survival, ENDOMETRIAL surgery, CHEMORADIOTHERAPY |
| مستخلص: |
Aim: We planned this study to assess endometrial cancer (EC) patients who had late metastasis. Materials and Methods: This retrospective study constituted a review of the records of patients who were diagnosed with EC and underwent hysterectomy at the Gynecologic Oncology Clinic between 1996 and 2018. Relapses occurring after the first three years following primary treatment of EC are considered late recurrences. Post-relapse survival (PRS) refers to the time to the last follow-up or the patient's death after relapse. Results: Late metastases were identified in 42 patients, 20 (47.6%) of whom had locoregional recurrence and 22 of whom (52.4%) had extrapelvic recurrence. Median disease-free survival (DFS) times were 61 (range: 43-78) and 65 (range: 48-81) months for the groups with locoregional and extrapelvic recurrences, respectively (P = 0.462). The 5-year PRS rate for the patients was 61.1%, with 63.8% having locoregional and 59.4% having extrapelvic late metastasis (P = 0.969). Conclusion: Among the patients with late metastases, those with endometrioid type EC were found to have a better prognosis. It has been shown that locoregional or extrapelvic organ recurrence does not significantly affect survival in patients with late relapse. Although our results are not statistically significant for cases of locoregional late metastases, surgical resection increases survival rates. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cancer Research & Therapeutics is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder